Roivant Sciences Ltd Ordinary Shares ROIV 深 沪
已收盘 09-12 16:00:00 美东时间
14.08
-0.330
-2.29%
华盛通- 最 高14.47
- 今 开14.40
- 成交量 758.79万股
- 最 低 14.07
- 昨 收 14.41
- 总市值 96.17亿
- 52周最高 14.475
- 市盈率 静 --
- 换手率 1.11%
- 52周最低 8.73
- 委 比 53.93%
- 总股本 6.83亿
- 历史最高 16.76
- 量 比 0.73
- 振 幅 2.78%
- 历史最低 2.52
- 每 手 1
- 风险率 0.89%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Roivant Sciences Approves Proposals at Annual Meeting
An update from Roivant Sciences ( ($ROIV) ) is now available. On September 10, ...
09-12 05:29
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
<p>Roivant首次入选2025年Fortune最佳生物制药 workplaces名单，排名第28位（小中型企业类别）。该评选基于Great Place To Work的Trust Index™ Survey，分析了近4万员工的反馈。Roivant CEO Matt Gline表示，这一荣誉反映了团队致力于打造赋能、高绩效、人才驱动的企业文化。Fortune最佳生物制药 workplaces名单基于员工体验的六个关键问题，旨在选出为所有员工提供积极工作体验的公司。Roivant通过创建敏捷子公司“Vants”推动药物开发，并致力于改善患者生活。</p>
09-11 20:30
Roivant Sciences Announces Promising Study Results
Roivant Sciences ( ($ROIV) ) has provided an update. On September 3, 2025, Roiv...
09-04 01:57
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
<p>Immunovant's batoclimab shows promising results for uncontrolled Graves' disease patients, with 80% achieving normal thyroid function after six months off treatment. Of these, 50% achieved anti-thyroid drug-free remission. Two registrational trials for IMVT-1402 are ongoing, with results expected in 2027. Immunovant will discuss these updates during an investor call on September 3, 2025.</p>
09-03 17:01
Citigroup Initiates Coverage On Roivant Sciences with Buy Rating, Announces Price Target of $16
Citigroup analyst Samantha Semenkow initiates coverage on Roivant Sciences (NASDAQ:ROIV) with a Buy rating and announces Price Target of $16.
09-02 20:02
Roivant Sciences Q1 2026 Adj. EPS $(0.25) Beats $(0.30) Estimate, Sales $2.170M Down From $7.990M YoY
Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.30) by 16.67 percent. This is a 47.06 percent decrease over losses of $(0.17) per share from
08-11 19:05
Earnings Scheduled For August 11, 2025
Companies Reporting Before The Bell • Niu Techs (NASDAQ:NIU) is expected to rep...
08-11 16:32
A Glimpse of Roivant Sciences's Earnings Potential
Roivant Sciences (NASDAQ:ROIV) is preparing to release its quarterly earnings o...
08-08 22:05
470亿港元合作：晶泰控股与哈佛教授Verdine创AI制药史上合作订单新纪录
2025年8月5日，晶泰控股（02228.HK）宣布与哈佛大学教授Gregory Verdine创立的DoveTree正式签署最终协议，合作总规模达470亿港元...
08-07 11:50
Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025
Roivant announced it will host a live conference call and webcast on August 11, 2025, at 8:00 a.m. ET, to discuss its Q1 2025 financial results and provide a business update. Registration for the call is available via a provided link, and webcast details will be accessible on its投资者 section. Roivant, a biopharmaceutical company, focuses on accelerating medicine development and commercialization, with a pipeline including IMVT-1402, batoclimab, br...
07-28 20:05
